EP1546100A4 - Neue benzoylpiperidinverbindungen - Google Patents

Neue benzoylpiperidinverbindungen

Info

Publication number
EP1546100A4
EP1546100A4 EP03792860A EP03792860A EP1546100A4 EP 1546100 A4 EP1546100 A4 EP 1546100A4 EP 03792860 A EP03792860 A EP 03792860A EP 03792860 A EP03792860 A EP 03792860A EP 1546100 A4 EP1546100 A4 EP 1546100A4
Authority
EP
European Patent Office
Prior art keywords
benzoyl compounds
racemic
nervous system
central nervous
new benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03792860A
Other languages
English (en)
French (fr)
Other versions
EP1546100A1 (de
EP1546100B1 (de
Inventor
Yong-Moon Choi
Yong-Kil Kim
Jin-Uk Yoo
Eun-Ah Paek
Chun-Eung Park
Sung-Yong Seo
Coo-Min Chung
Joon Heo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Inc
Original Assignee
SK Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1546100(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Corp filed Critical SK Corp
Publication of EP1546100A1 publication Critical patent/EP1546100A1/de
Publication of EP1546100A4 publication Critical patent/EP1546100A4/de
Application granted granted Critical
Publication of EP1546100B1 publication Critical patent/EP1546100B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP03792860A 2002-08-26 2003-08-19 Neue benzoylpiperidinverbindungen Expired - Lifetime EP1546100B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/228,869 US6770659B2 (en) 2002-08-26 2002-08-26 Benzoyl piperidine compounds
US228869 2002-08-26
PCT/KR2003/001665 WO2004018423A1 (en) 2002-08-26 2003-08-19 New benzoyl piperidine compounds

Publications (3)

Publication Number Publication Date
EP1546100A1 EP1546100A1 (de) 2005-06-29
EP1546100A4 true EP1546100A4 (de) 2007-10-31
EP1546100B1 EP1546100B1 (de) 2011-04-20

Family

ID=31946347

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03792860A Expired - Lifetime EP1546100B1 (de) 2002-08-26 2003-08-19 Neue benzoylpiperidinverbindungen

Country Status (15)

Country Link
US (1) US6770659B2 (de)
EP (1) EP1546100B1 (de)
JP (1) JP4674686B2 (de)
KR (1) KR100614301B1 (de)
CN (1) CN100338037C (de)
AT (1) ATE506348T1 (de)
AU (1) AU2003251206B2 (de)
BR (1) BR0313922A (de)
CA (1) CA2496678C (de)
DE (1) DE60336830D1 (de)
ES (1) ES2364749T3 (de)
MX (1) MXPA05002366A (de)
RU (1) RU2342363C2 (de)
TW (1) TWI334413B (de)
WO (1) WO2004018423A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4855485B2 (ja) * 2006-02-17 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー ５ｈｔ２／ｄ３モジュレーターとしてのベンゾイル−ピペリジン誘導体
ES2379848T3 (es) * 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
JP2013503835A (ja) * 2009-09-07 2013-02-04 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なエタンジアミン系ヘプシジン拮抗薬
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124476A1 (de) * 1983-03-09 1984-11-07 Ciba-Geigy Ag Carboxamide, Verfahren zur Herstellung und pharmazeutische Präparate, die diese enthalten
EP0261688A1 (de) * 1986-09-26 1988-03-30 Sumitomo Pharmaceuticals Company, Limited Imid-Derivate, ihre Herstellung und ihre Verwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
US4415581A (en) * 1982-04-09 1983-11-15 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines to treat psychoses
ZA841728B (en) * 1983-03-09 1984-11-28 Ciba Geigy Ag Novel carboxamides
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
EP0222702A3 (de) * 1985-11-06 1988-01-07 Ciba-Geigy Ag Basische Carbonylverbindungen
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
US4812456A (en) 1987-05-13 1989-03-14 Hoechst-Roussel Pharmaceuticals Inc. 1-(N-(2-alkylthio-10H-phenothiazin-10-yl)alkyl)-4-benzoylpiperidines and pharmaceutical use
JPH03130263A (ja) * 1989-07-19 1991-06-04 Eisai Co Ltd 光学活性ナフチルエタノール誘導体
US5114936A (en) 1990-08-23 1992-05-19 Hoechst-Roussel Pharmaceuticals Incorporated 6,7-dihydro-3-phenyl-1,2-benzisoxazol-4(5h)-ones and -ols, compositions and pharmaceutical use
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
IL118768A (en) * 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
TR200000916T2 (tr) * 1997-10-07 2000-07-21 Akzo Nobel N.V. İkameli piperidin türevleri.
US6363604B1 (en) * 1999-05-21 2002-04-02 Autonetworks Technologies, Ltd. Method and apparatus for cutting braided sheath of shielding wire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124476A1 (de) * 1983-03-09 1984-11-07 Ciba-Geigy Ag Carboxamide, Verfahren zur Herstellung und pharmazeutische Präparate, die diese enthalten
EP0261688A1 (de) * 1986-09-26 1988-03-30 Sumitomo Pharmaceuticals Company, Limited Imid-Derivate, ihre Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
ATE506348T1 (de) 2011-05-15
CN1678582A (zh) 2005-10-05
RU2005108569A (ru) 2005-08-27
ES2364749T3 (es) 2011-09-13
AU2003251206B2 (en) 2009-05-28
EP1546100A1 (de) 2005-06-29
BR0313922A (pt) 2005-07-19
CA2496678A1 (en) 2004-03-04
TWI334413B (en) 2010-12-11
CA2496678C (en) 2011-06-14
CN100338037C (zh) 2007-09-19
RU2342363C2 (ru) 2008-12-27
MXPA05002366A (es) 2005-05-23
TW200404781A (en) 2004-04-01
US20040044033A1 (en) 2004-03-04
US6770659B2 (en) 2004-08-03
JP4674686B2 (ja) 2011-04-20
KR20050038027A (ko) 2005-04-25
KR100614301B1 (ko) 2006-08-22
EP1546100B1 (de) 2011-04-20
WO2004018423A1 (en) 2004-03-04
DE60336830D1 (de) 2011-06-01
AU2003251206A1 (en) 2004-03-11
JP2006502146A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
JP2005532372A5 (de)
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
MY137509A (en) Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20054228L (no) Anvendelse av (IS,2R)-enantiomeren av milnacipran for fremstillingen av et medikament
EA200401365A1 (ru) Способы лечения илеуса
ATE426405T1 (de) Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DK1678172T3 (da) Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
BR0314631A (pt) Derivados de pirrolidona como inibidores de maob
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
EP1546100A4 (de) Neue benzoylpiperidinverbindungen
DE50108339D1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
EP1575548A4 (de) Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
BR0010961A (pt) Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071002

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/45 20060101ALI20070926BHEP

Ipc: C07D 401/06 20060101ALI20070926BHEP

Ipc: A61P 25/18 20060101ALI20070926BHEP

Ipc: C07D 401/12 20060101ALI20070926BHEP

Ipc: C07D 211/16 20060101AFI20040318BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SK HOLDINGS CO., LTD.

17Q First examination report despatched

Effective date: 20090312

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60336830

Country of ref document: DE

Date of ref document: 20110601

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60336830

Country of ref document: DE

Effective date: 20110601

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110420

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2364749

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110721

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60336830

Country of ref document: DE

Representative=s name: KADOR & PARTNER, DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120216 AND 20120222

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60336830

Country of ref document: DE

Representative=s name: KADOR & PARTNER, DE

Effective date: 20120131

Ref country code: DE

Ref legal event code: R081

Ref document number: 60336830

Country of ref document: DE

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Free format text: FORMER OWNER: SK HOLDINGS CO., LTD., SEOUL, KR

Effective date: 20120131

Ref country code: DE

Ref legal event code: R081

Ref document number: 60336830

Country of ref document: DE

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Free format text: FORMER OWNER: SK CORP., SEOUL/SOUL, KR

Effective date: 20110324

Ref country code: DE

Ref legal event code: R082

Ref document number: 60336830

Country of ref document: DE

Representative=s name: KADOR & PARTNER PART MBB PATENTANWAELTE, DE

Effective date: 20120131

Ref country code: DE

Ref legal event code: R082

Ref document number: 60336830

Country of ref document: DE

Representative=s name: KADOR & PARTNER PARTG MBB PATENTANWAELTE, DE

Effective date: 20120131

26N No opposition filed

Effective date: 20120123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: SK BIOPHARMACEUTICALS CO., LTD.

Effective date: 20120409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60336830

Country of ref document: DE

Effective date: 20120123

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110420

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200825

Year of fee payment: 18

Ref country code: FR

Payment date: 20200824

Year of fee payment: 18

Ref country code: ES

Payment date: 20200923

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200820

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20201029

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60336830

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210819

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210819

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220301

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210820